BIOSPECIFICS TECHNOLOGIES CORP Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2015-11-18: Form 8-K; Period of report 2015-11-18; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2015-11-10: Form 8-K; Period of report 2015-11-10; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2015-11-09: Form 8-K; Period of report 2015-11-09; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2015-11-06: Form 8-K; Period of report 2015-11-06; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2015-11-18 | 8-K | 2015-11-18 | 7.01 Regulation FD Disclosure | 7.01 Officers and representatives of the Company will present to various investors and stockholders beginning November 18, 2015 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2015-11-10 | 8-K | 2015-11-10 | 7.01 Regulation FD Disclosure | 7.01 Officers and representatives of the Company will present to various investors and stockholders beginning November 10, 2015 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2015-11-09 | 8-K | 2015-11-09 | 2.02 Results of Operations and Financial Condition | 2.02 On November 9, 2015, the Company announced its financial and operating results for the fiscal quarter ended September 30, 2015. | form8k.htm |
| 2015-11-06 | 8-K | 2015-11-06 | 8.01 Other Events | 8.01 On November 5, 2015, BioSpecifics announced that its partner Endo International plc (“Endo”) had exercised, with BioSpecifics’ consent, an early opt-in right for CCH to include two new potential indications, plantar fibromatosis and lateral thigh fat. | form8k.htm |
| 2015-10-05 | 8-K | 2015-10-05 | 7.01 Regulation FD Disclosure | 7.01 Officers and representatives of the Company will present to various investors and stockholders beginning October 5, 2015 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2015-09-21 | 8-K | 2015-09-21 | 8.01 Other Events | 8.01 On September 21, 2015, BioSpecifics announced that the first commercial sale of XIAFLEX by Asahi Kasei Pharma Corporation for the treatment of Dupuytren's contracture in Japan has triggered a $1.0 million milestone payment to BioSpecifics. | form8k.htm |
| 2015-09-03 | 8-K | 2015-09-03 | 7.01 Regulation FD Disclosure | 7.01 Officers and representatives of the Company will present to various investors and stockholders beginning September 3, 2015 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2015-08-31 | 8-K | 2015-08-31 | 8.01 Other Events | 8.01 On August 31, 2015, the Company announced the formal pricing of XIAFLEX for the treatment of patients with Dupuytren’s contracture in Japan and that BioSpecifics will receive a milestone payment upon the first commercial sale of XIAFLEX in Japan. | form8k.htm |
| 2015-08-17 | 8-K | 2015-08-17 | 8.01 Other Events | 8.01 On August 17, 2015, the Company issued a press release announcing that its Board of Directors has authorized the repurchase of up to $2,500,000 of its outstanding common stock. | form8k.htm |
| 2015-08-12 | 8-K | 2015-08-12 | 7.01 Regulation FD Disclosure | 7.01 Officers and representatives of the Company will present to various investors and stockholders beginning August 12, 2015 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2015-08-10 | 8-K | 2015-08-10 | 2.02 Results of Operations and Financial Condition | 2.02 On August 10, 2015, the Company announced its financial and operating results for the fiscal quarter ended June 30, 2015. | form8k.htm |
| 2015-07-20 | 8-K | 2015-07-20 | 8.01 Other Events | 8.01 On July 20, 2015, the Company announced that Asahi Kasei Pharma Corporation had received approval for its regulatory application to the Japanese Pharmaceutical and Medical Device Agency to manufacture and sell XIAFLEX® (collagenase clostridium histolyticum) for the treatment of patients with Dupuytren’s contracture in Japan. | form8k.htm |
| 2015-06-19 | 8-K | 2015-06-19 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The 2015 annual meeting of stockholders of the Company (the “2015 Annual Meeting”) was held on June 18, 2015. | form8k.htm |
| 2015-06-01 | 8-K | 2015-06-01 | 7.01 Regulation FD Disclosure | 7.01 Officers and representatives of the Company will present to various investors and stockholders beginning June 1, 2015 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2015-05-20 | 8-K | 2015-05-19 | 2.02 Results of Operations and Financial Condition | 2.02 On May 19, 2015, the Company announced that its strategic partner Endo International plc presented XIAFLEX efficacy data and the first ever treatment guidelines for Peyronie’s disease at the American Urological Association 2015 Annual Meeting in New Orleans, Louisiana. | form8k.htm |
| 2015-05-18 | 8-K | 2015-05-18 | 7.01 Regulation FD Disclosure | 7.01 Officers and representatives of the Company will present to various investors beginning on May 18, 2015 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2015-05-11 | 8-K | 2015-05-11 | 2.02 Results of Operations and Financial Condition | 2.02 On May 11, 2015, the Company announced its financial and operating results for the fiscal quarter ended March 31, 2015. | form8k.htm |
| 2015-04-22 | 8-K | 2015-04-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 22, 2015, pursuant to Section 2.2 of the Company’s Amended and Restated By-laws (the “Bylaws”), the Board of Directors increased the number of directors on the Board of Directors by (1) to eight (8) members resulting in two (2) vacancies. | form8k.htm |
| 2015-04-13 | 8-K | 2015-04-13 | 7.01 Regulation FD Disclosure | 7.01 Officers and representatives of the Company will present to various investors and stockholders beginning April 13, 2015 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2015-03-19 | 8-K | 2015-03-19 | 7.01 Regulation FD Disclosure | 7.01 Officers and representatives of the Company will present to various investors and stockholders beginning March 19, 2015 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2015-03-13 | 8-K | 2015-03-13 | 2.02 Results of Operations and Financial Condition | 2.02 On March 13, 2015, the Company announced its financial and operating results for the fiscal quarter and full year ended December 31, 2014. | form8k.htm |
| 2015-03-04 | 8-K | 2015-03-03 | 7.01 Regulation FD Disclosure | 7.01 Officers and representatives of the Company will present to various investors and stockholders beginning March 4, 2015 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2015-02-23 | 8-K | 2015-02-23 | 7.01 Regulation FD Disclosure | 7.01 Officers and representatives of the Company will present to various investors and stockholders beginning February 23, 2015 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2015-02-02 | 8-K | 2015-02-02 | 8.01 Other Events | 8.01 On February 2, 2015, the Company announced that the EU Commission has approved XIAPEX® (collagenase clostridium histolyticum) for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. | form8k.htm |
| 2015-01-12 | 8-K | 2015-01-12 | 7.01 Regulation FD Disclosure | 7.01 Officers and representatives of the Company will present to various investors and stockholders beginning on January 12, 2015 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |